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DEVELOPMENT OF AN UFLC/MS/MS METHOD FOR THE COMPARATIVE 
ANALYSIS OF OXYTOCIN AND ARTESUNATE-AMODIAQUINE FOR 
VALIDATION OF FIELD DETECTION SYSTEMS 
 
 
DAVID ANDREW GODIN 
 
ABSTRACT 
 Spurious, falsely-labeled, falsified or counterfeit (SFFC) pharmaceuticals 
are a health concern that claims hundreds of thousands of lives annually1, a 
violation of intellectual property rights which cost legitimate companies billions2, 
and a low-risk high yield revenue stream for organized crime2.  While ports of 
entry and border control points are the primary access control points for SFFC3,4, 
advances in field portable detection and equipment offers an increasingly 
effective method for the assessment of pharmaceuticals at regional centers and 
points of distribution.  This is particularly important for less developed countries 
(LDC) who do not maintain satellite or regional testing facilities. 
          As part of a proposed protocol to assess field portable detection 
equipment, an ultrafast liquid chromatography, tandem mass spectrometry 
(UFLC-MS/MS) method for the quantification of liquid formulation Oxytocin was 
developed.  The six minute method was found to have a within run %bias of +/-
16%, a linear dynamic range of 150-1000 nanograms/milliliter (ng/ml), and an 
accuracy within acceptability criteria for all tested concentrations. 
 The effectiveness of three identified transition ions, 723.1, 86.2 and 70.1 
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Daltons, for the analysis of oxytocin by mass spectrometry was assessed across 
several figures of merit to include signal to noise ratio, %CV, calibration 
sensitivity, and analytical sensitivity.  The 723.1 ion fragment was recommended 
for quantification, while the 70.1 dalton ion was recommended as a qualifier ion, 
although 86.2 also performed within acceptability criteria. 
 A method for the UFLC-MS/MS assessment of degradation products for 
oxytocin was proposed for specificity testing.  Degradation of oxytocin by 
exposure to highly acidic, basic, and thermal conditions for one hour was 
attempted.  Formation of degraded products was not observed. 
 Additionally, existing High Performance Liquid Chromatography (HPLC) 
methods for the simultaneous assessment of Artesunate and Amodiaquine HCl 
were modified to assess compatibility with UFLC.  No method assessed 
produced sufficient quality signal to continue with method development. 
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1. INTRODUCTION 
 
1.1 Counterfeit and Substandard Medicines  
Counterfeit and substandard medicines are a serious global health 
concern, estimated to contribute to hundreds of thousands of deaths per year1,3.  
In China alone 200,000-300,000 persons die each year due to counterfeit or 
substandard medicines3.  Referred to as “spurious/falsely-
labelled/falsified/counterfeit (SFFC) medicines by the World Health Organization 
(WHO), these medicines may vary from harmful or toxic substances labelled as 
legitimate medicine, to preparations containing incorrect, inactive, or ineffective 
doses of active pharmaceutical ingredients (API)4. 
The impact of counterfeit drugs is felt in wealthy countries as well as less 
developed countries (LDC).  Industrialized countries are protected by strict 
manufacturing guidelines, regulations, and importation controls.  In just two 
months in 2008, 34 million illegal pills were seized across the external borders of 
the European Union (EU)5 alone, while United States authorities are estimated to 
prevent approximately 75 billion dollars’ worth of counterfeit medicines from 
entering circulation annually2.  Because of the effectiveness of these systems, 
only an estimated 1% of medicine in legal circulation is counterfeit4.  In these 
industrialized countries, the internet is the primary source of SFFCs.  The WHO 
reports that medicine purchased from illegal internet sites were counterfeit in 
more than 50% of observed cases4. 
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Less developed countries do not benefit from the controls and protective 
regulations and robust systems enjoyed by wealthy countries, the dangers posed 
by SFFCs are ubiquitous and difficult to measure.  The WHO estimates that 25% 
of medicines in LDCs are counterfeit3,4, although this varies by geographic region 
and product.  Chinese authorities report counterfeit rates between 50 and 85% 
for some products, while in Nigeria and Thailand, an estimated 36.5% of 
antibiotics and antimalarials in circulation are counterfeit or substandard3.  
Antimalarial and antibiotic courses of treatment rely on steady, regular dosing 
over long periods of time.  Interrupting the dosing with substandard or counterfeit 
medications can cause the treatment to fail and contributes to the resistance of 
those infections against future treatment. 
In addition to a global health concern, SFFC is a billion dollar black market 
with links to organized crime, and represents a significant loss of income to 
legitimate pharmaceutical companies.  For example, counterfeit Viagra 
(sildenafil) is estimated to cost Pfizer Inc. two billion United States Dollars (USD) 
annually in sales2.  The United Nations Interregional Crime and Justice Research 
Institute (UNICRI) notes that pharmaceutical counterfeit is a low risk, high profit 
illegal activity that is used to fund the production and trafficking of controlled 
substances, illegal arms dealing, money laundering, and human trafficking2.  One 
kilogram (kg) of counterfeit Viagra has a lower production cost than 1 kg of 
heroin, possess a higher street value than heroin, is not as heavily policed or 
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penalized as the distribution of a controlled substance2, and represents a low 
risk, high yield revenue stream for organized crime. 
 
1.1.1 Combatting Counterfeit Pharmaceuticals 
 Any strategy for combatting counterfeit pharmaceuticals must functionally 
rely on a method of determining the authenticity of medicine in circulation.  This 
is done primarily at ports of embarkation and debarkation, or at regional 
collection and distribution centers. Additionally, the United States Pharmacopeia 
(USP) has published drug quality monitoring procedures for assessing medicine 
in local circulation.  These guidelines cover sampling, transportation, and storage 
protocols, as well as testing6.  This methodology begins with a physical and 
visual inspection of the sample and its associated packaging compared to 
published standards.  Many pharmaceutical companies have distinct 
manufacturer logos, markings, and water marks incorporated into their packaging 
to make forgery difficult.  Second, a disintegration test is conducted to verify the 
label’s stated enteric-coating and time release claims.  Artesunate, for example, 
should dissolve in pure water at 37˚C in less than 30 minutes or it is considered a 
major defect7.  Next, the active pharmaceutical ingredient’s presence is verified, 
typically through nonspecific colorimetric reagent testing.  Finally an assessment 
by thin layer chromatography is made to verify the potency of the drug in 
question against a generated standard curve.  Once these initial tests are 
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complete, the USP then recommends confirmatory and validation testing based 
upon current approved methods in regional satellite laboratories6. 
 This field monitoring program relies chiefly on German Pharma Health 
Fund’s (GPHF) Minilab® to perform field analysis6.  This Minilab is a reagent-
based testing kit specifically designed for counterfeit pharmaceutical detection in 
developing world nations, and has an associated cost of $6/assay8 in US dollars.  
These tests still require laboratory confirmation at satellite laboratories or 
regional laboratories. 
1.1.2 Field Portable Analytical and Screening Technology 
 Improvements in miniaturization and portability of laboratory technology 
allow for confirmatory testing, normally associated with regional laboratories, to 
be employed directly at the testing sites.  Field portable Fourier Transform 
Infrared Spectrometers (FTIR), Raman Spectroscopy, Gas Chromatography/ 
Mass Spectrometry (GC/MS), and even Polymerase Chain Reaction (PCR) are 
available 9–11.  These portable systems allow forward confirmatory testing in 
regions without satellite laboratories. 
Developing technology may feasibly replace the GPHF Minilab® as a 
direct analytical tool for forward field screening.  One portable screening system 
in development is the PharmaChk.  The device is capable of providing field 
screening and quantification1.  It consists of four basic components: A tablet 
dissolving chamber, a fluorescent tag, a microfluidic chip and the signal 
detector1.  The fluorescent tag utilized by the system gives the platform its 
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modularity.  A different probe is developed for each active pharmaceutical 
ingredient (API).  Some analytes are detectable with well-studied chemical 
interactions, such as the luminol interactions used to detect artesunate1.  Other 
probes utilize highly specific aptamer binding interaction to create a detectable 
fluorescent response1. Each method must be assessed in its ability to selectively 
bind to the target analyte of interest.  This requires that each method’s specificity 
be assessed against common counterfeit adulterants, and the analyte’s own 
natural degradation products. 
  
1.1.3 Assessing Field Portable Analytical and Screening Technology 
 As new and emerging technologies are developed, their effectiveness for 
screening and identifying counterfeit pharmaceuticals must be evaluated.  This 
evaluation should address the technology’s ability to detect the API in question at 
a therapeutic concentration, the ability to differentiate between API and common 
adulterants found in counterfeit pharmaceuticals, and also the method’s ability to 
discriminate between active and inactive pharmaceutical ingredients. 
 For this assessment two medications were chosen from the World 
Health’s Organization’s essential medicine list11–13;  Oxytocin (OT) and 
Artesunate/Amodiaquine (AT/AQ).  Oxytocin represents a high risk counterfeit 
drug, as it is an immediate use therapeutic drug.  A counterfeit or substandard 
formulation could fail to induce labor, or fail to reduce post partum hemorrhage, 
endangering both child and mother. Thus, oxytocin is utilized in order to test the 
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feasibility of the proposed field-device on liquid formulations.  
Artesunate/Amodiaquine, on the other hand, is a commonly encountered 
counterfeit drug representative of the normal challenges expected by a screening 
device, and measures the proposed device’s ability to assess a tablet3 . 
 
1.2 Oxytocin 
 
Figure 1.  Oxytocin H-c[Cys-Tyr-Ile-Gln-Asn-Cys]-Pro-Leu-Gly-NH2, showing the biologically active disulfide 
bond between Cys1-Cys6.15   
 
 Oxytocin is a cyclic nonapeptide with a molecular weight (MW) of 1007.16 
Daltons, and is the most commonly utilized peptide drug in medicine15,16.  Its 
structure is depicted in Figure 1.  Oxytocin is used therapeutically to induce labor 
through the stimulation of uterine contractions17.  It is also used at higher doses 
to reduce post-partum hemorrhage, a significant source of maternal deaths in 
developing countries18.  Counterfeit or substandard oxytocin can fail to stimulate 
uterine contractions, elongating the birthing process and endangering both 
mother and child17.   
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 Oxytocin is inactivated in the gastrointestinal tract17 and is therefore 
administered in solution through either intramuscular (IM) injections or through 
intravenous (IV) solution.  Its therapeutic range is from .02 units per milliliter 
(units/ml) to .12 units/ml, or 40-240 nanograms per milliliter (ng/ml)19.  Because 
oxytocin is only stable in saline for approximately 27 days16, it is typically 
encountered in 1 ml ampules of 10 units/ml, or 17-25 micrograms, designed for 
injection into saline solution.  Oxytocin may also be transported as a powder, but 
this powder formulation was determined to be unfit for tropical climates by the 
WHO13 due to its poor stability, and was excluded from assessment for this 
reason.  
 Despite the fact that synthetic oxytocin has been utilized in medicine since 
the early 1950s15,18, little is known about its degradation products or mechanism. 
Hawe et. al demonstrated in 2009 that oxytocin degradation was pH- and 
temperature- dependent and followed first order kinetics18.  It was further 
demonstrated that the degradation products were resolvable from the precursor 
compound through reverse phase high performance liquid chromatography (RP-
HPLC) and detectable by ultraviolet-visible light spectroscopy (UV-VIS)18. Hawe  
identified the observed degradation products as species of deamidated oxytocin.  
A deamidation reaction, or R-CONH2R-COOH, creates a mass difference of 
0.985 daltons18.  Hawe further identified three sites at which deamidation 
occurred by collecting each RP-HPLC peak fraction separately, linearizing 
oxytocin’s ring structure through reduction with dithiothreitol (DTT), and then 
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conducting structural analysis by MS/MS fragmentation analysis.  Hawe identified 
three sites for deamidation; the C-terminal Gly9, the Asn5 or the Gln4.    
The mechanism by which Oxytocin decays was studied by Wisniewski et 
al in 2013.  Wisniewski utilized sixteen synthesized OT analogues with modified 
structures and labeled 34S and 13C, which were incubated in an aqueous solution 
and stressed to facilitate degradation.  The structure of the reaction products was 
examined by mass spectroscopy (MS) and nuclear magnetic resonance (NMR)15. 
Wisniewski suggests that the degradation of oxytocin begins by cleavage of the 
disulfide bridge between the Cystene1  and Cystene6 peptides through β-
elimination.  The resultant intermediate is a linear peptide which has a persulfide 
(S-thiocysteine), which Wisniewski suggests donates a sulfur atom to intact 
oxytocin molecules to create oxytocin trisulfide and other monomeric 
polysulfides15. These products were demonstrated to be resolvable by HPLC, 
and detectable by MS, but it is of note that the oxytocin polysulfides appear 
during incubation, but do not accumulate in concentration as oxytocin 
concentration decreases, suggesting that the persulfide and polysulfide products 
serve as intermediates, with the major degradation product being a dimer with a 
proposed structure shown in Figure 215. The deamidated products noted by 
Hawe are not addressed by Wisniewski’s degradation mechanism.  It is unclear if 
the degradation products identified in either study are biologically active, 
although the 20-membered, six amino acid ring is considered a key structural 
feature of OT15. 
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Figure 2.  Proposed structure of the major dimeric product of oxytocin degradation in an aqueous 
environment proposed by K. Wisniewski et. al in 201315.   
 
1.3 Artesunate  
 
Figure 3.  Chemical structure of artesunate20 
  
Artesunate (Figure 2) is an anti-inflammatory, anti-malarial compound20.  
Artesunate (AT) is a semi-synthetic derivative of artemisinin21, which is isolated 
from the herb Artemisia annua.  It is the most commonly used treatment to 
combat malaria, the infection spread by the parasite Plasmodium falciparum, and 
is most effective against the ring stage of the parasite21.  Malaria is a serious 
global health concern, with over 247 million cases reported in 2008 alone22. 
Malaria results in nearly one million deaths annually, with a majority of those 
deaths reported in African children under 5 years of age22. 
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 Artesunate has relatively well studied degradation products.  Haynes et al 
demonstrated in 2007 that, when heated, artesunate degrades into β-artesunate, 
artesunate dimers, and 9,10-anhydrodihydroartemisinin23.  Haynes utilized NMR 
to identify products, rather than HPLC.  Existing methods using HPLC-UV/VIS 
demonstrate that artesunate may be resolved from common impurities (with the 
exception of chloroquinine phosphate and monodesethylamodiaquine 
dihydrochloride)22,23.   Artesunate has a short biological half-life, and is often 
paired with a second medication as an antimalarial combination therapy (ACT).   
 
1.4 Amodiaquine Hydrochloride 
 
Figure 3.  Chemical Structure of Amodiaquine Hydrochloride 
 
         Amodiaquine hydrochloride (AQ) is an antimalarial chemically similar to 
chloroquine, and is commonly used to treat resistant strains of Plasmodium 
falciparum.   Artesunate-Amodiaquine combination therapy (ACT) is a widely 
used treatment for malaria22.   RajaRao et al conducted forced degradation of 
artesunate and amodiaquine in 2013, but did not observe additional product 
peaks through HPLC/UV-VIS analysis.  Further, no significant shift in the 
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retention times (RT) of precursor compound peaks20 was observed.  This 
indicates that products may not have formed, or that any products that formed 
were either not resolved through HPLC, or not detected by UV-VIS.   
 
1.5 Ultrafast Liquid Chromatography 
 Several methods for the analysis of AT, AQ, and AT/AQ simultaneously 
are available. A number of these methods utilize HPLC coupled with UV-VIS 
detection20–23. Early degradation studies were conducted using UV-VIS detection, 
which may detect and quantify a compound, but offers limited structural 
information20,22. 
 Ultrafast liquid chromatography (UFLC), like high pressure liquid 
chromatography (HPLC), exploits differences in the affinity of an analyte of 
interest (AOI) with a stationary phase24.  The stationary phase typically contains 
functionalized silica.  Liquid chromatography is based upon the premise that two 
different chemical compounds will have different affinities for the stationary phase 
resulting in different RTs.  If RT are sufficiently different between two 
compounds, they may be resolved or purified by HPLC.  This travel time, or RT is 
further managed in liquid chromatography by selectively altering the liquid mobile 
phase.  By controlling the mobile phase’s polarity, pH, or ion content in controlled 
gradients, it is possible to alter the RT of the analytes of interest.  This, combined 
with high pressure and increased column efficiency over HPLC and LC systems, 
allows for shorter method times, smaller samples, and decreased solvent use24. 
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1.6 Electrospray Ionization 
 As the analyte of interest reaches the end of the UFLC column, it is 
ionized by electrospray ionization (ESI).  ESI is a soft ionization technique which 
occurs under atmospheric conditions25,26.  The sample in the mobile phase is 
ionized at the ESI source by a coronal discharge of energy, which aerosolizes 
the solvent into charged droplets26.  The net charge of the droplet causes each 
individual droplet to explode due to accumulated coulombic force, forming ions 
which enter the mass spectrometer25.  ESI was utilized in positive ion mode for 
the duration of protocol development, creating ions of molecular weight (M) plus 
a single hydrogen (H) or M+H26.  Because this process occurs under 
atmospheric conditions, rather than a vacuum, conditions between two similar 
instruments may vary.  The ions created from the ESI process are then directed 
into a mass spectrometer. 
 
1.7 Tandem Mass Spectrometry 
   The ions created during the ionization process are separated and detected 
based upon their mass to charge ratio (m/z).  This is accomplished using a 
quadrupole, or four parallel poles conducting direct current or radio frequency 
current to create a field through which only the correct m/z may pass26.  The 
applied current separates larger ions from smaller ions, allowing for a separation 
of ions of different masses based upon their mass to charge ratio. Further for this 
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experiment, a triple quadrupole was utilized.  In this arrangement, three 
quadrupoles are arranged in series.  The first quadruple (Q1) allows only the 
precursor ion (M+H) to pass, filtering all other ions out and greatly increasing 
precision while decreasing noise from unassociated ions.  The second quadruple 
(Q2) fragments this precursor ion into additional “product” or fragment ions, 
which are then selectively analyzed in (Q3)25.  This resulting precursor to product 
fragmentation pattern allows for the creation of a chemical fingerprint which may 
be used to identify a compound as well as offer some insight to its chemical 
structure.  The triple quadrupole mass spectrometer was selected for this study 
due to its ability to not only detect degradation products which may not have 
been detected through UV-VIS analysis, but also provide insight to the structure 
and identity of any degradation products identified in this study. 
14 
2. MATERIALS AND METHODS 
 
2.1  Standards 
 
2.1.1  Oxytocin 
 Oxytocin was purchased from Caymen Chemical (Ann Arbor, Michigan) as 
a vial of 1 milligram (mg) lyophilized powder.  A stock solution was prepared by 
adding either 1 milliliter (ml) of Deionized water or 1 ml of methanol, depending 
on the experiment.  Oxytocin prepared with Deionized water was stored in a 
refrigerator at a temperature of 5˚celsius (˚C), while oxytocin prepared in 
methanol was stored in a freezer at a temperature of -25 ˚C.  Certificates of 
analysis were received for all batches from Caymen Chemical, certifying a purity 
of 100% by UV-VIS analysis. 
 
2.1.2 Artesunate 
 100 mg of powdered artesunate was purchased from Sigma Aldrich (St. 
Louis, MO) and stored at room temperature (22 ˚C) in original packaging.  
Standards of artesunate were prepared by dissolving 1-2 mg in methanol to 
reach a concentration of either 1 mg/ml or 2 mg/ml, depending on the 
experiment.   
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2.1.3 Amodiaquine 
 Five grams (5 g) of powdered amodiaquine was purchased from Sigma 
Aldrich and stored at room temperature in original packaging.  Standards of 
amodiaquine were prepared by dissolving 1-2 mg in a sufficient volume methanol 
to reach a concentration of either 1 mg/ml or 2 mg/ml, depending on the 
experiment.   
 
2.2 Mobile Phase Preparation 
 All mobile phases were prepared using American Chemical Society 
certified HPLC grade or higher reagents.  Deionized water with a resistivity of at 
least 18 mΩ was used for these experiments and aliquoted daily. 
 For the analysis of Oxytocin, mobile phase A consisted of deionized water 
with .1% formic acid by volume.  This was prepared by the addition of 1 ml of 
formic acid to 900 ml of deionized water, before filling to a volume of 1000 ml 
with deionized water.   Mobile phase B consisted of HPLC grade acetonitrile 
(ACN) with .1% formic acid.  This was prepared by the addition of 1 ml of formic 
acid to 900 ml of acetonitrile before filling to a volume of 1000 ml with ACN. 
 
2.3 Instrumentation 
 The UFLC utilized in this protocol is a Shimadzu Prominence ultrafast 
liquid chromatography system from Shimadzu Corporation (Kyoto, Japan).  Mass 
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spectrometry was conducted using a 4000 QTrap® series from SCIEX 
(Framingham, MA).   A Phenomenex (Torrence, CA) Kinetex® 2.6 µm EVO C18 
100 Å LC Column (150x3.0 mm) normal phase column was used for the analysis 
and method development.  
 
2.4 Compound Optimization 
 Initial compound optimization was conducted by utilizing the automated 
compound optimization feature of the instrument’s operating software, Analyst® 
(version 1.6.2).  Values obtained from this automated optimization were used as 
the basis for performing a manual compound optimization by the protocol 
outlined in the operator’s manual by SCIEX for manual compound optimization27.  
Compound optimization was conducted at a concentration of 10 ng/ml of 
standard, with a flow rate of 10-25 ml/minute by direct infusion pump.  Ions 
selected were based primarily upon intensity, literature17,18, and reproducibility 
over multiple iterations of optimization.  This process is described in further detail 
in Section 3. 
   
2.5 Mobile Phase Selection 
 
 2.5.1 Oxytocin 
 The mobile phases selected for the analysis of oxytocin (Mobile Phase A: 
deionized water with .1% formic acid, Mobile Phase B: acetonitrile with .1% 
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formic acid) were selected based upon numerous existing and validated HPLC 
methods in the literature17–19,22,28.  These methods were adapted for a binary 
pump UFLC by separating organic phases (acetonitrile) as mobile phase B and 
replacing buffer solutions with Deionized water as mobile phase A, based upon 
manufacturer recommendations29, instrument configuration, and a previous 
optimization conducted by M. Liu30. 
 
2.5.2  Artesunate/Amodiaquine 
Several mobile phases were tested for use in the simultaneous analysis of 
artesunate and amodiaquine.  The mobile phases tested are included as 
Appendix A. 
  
2.6 Gradient Optimization 
 
2.6.1 Oxytocin Standard Curve 
The gradient selected for the generation of the oxytocin calibration curve 
and analysis is given in Table 1.  This gradient was selected by adapting an 
HPLC method30 to the shorter run time and higher pressures associated with 
UFLC, and further optimized by expanding the upper and lower limits of the 
gradient to reflect the region for which the peak shape remained in a Gaussian 
distribution.                                                                 
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Table 1. Oxytocin elution gradient and flow settings used for quantification 
 
Time (min) Gradient (%B) 
0.1 20 
1.5 20 
3.0 50 
4.5 50 
5.0 20 
Total Flow .5 mL/min 
Maximum Pressure  5000 psi 
 
2.6.2 Oxytocin Degradation Analysis: 
 The method used for the degradation analysis of oxytocin was three times 
the length of the quantification method.  This allowed for a longer, slower 
alteration of gradient that would be more likely to resolve degradation products of 
oxytocin, which are expected to have similar chemical structure and properties to 
the precursor compound.  The lower end of the gradient was expanded, while the 
upper limit of the gradient remained consistent due to a large increase in noise 
observed at high concentrations of mobile phase B during testing.  The gradient 
for the final method for the analysis of oxytocin degradation is provided as Table 
2. 
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Table 2. Elution gradient and flow settings for the assessment of oxytocin degradation products. 
Time (min) Gradient (%B) 
0.1 5 
1.0 5 
13 50 
14 5 
15 5 
Total Flow .5 mL/min 
Maximum Pressure 5000 psi 
 
2.7 Source and Acquisition Parameters 
 
2.7.1 Oxytocin Quantification 
 Source and Acquisition Parameters were optimized according to 
manufacturer protocols29 to maximize signal within normal operating parameters.  
The final source parameters used in the production of the calibration curve and 
subsequent analysis are described in Table 3.  The acquisition parameters used 
for the calibration curve are listed in Table 4. 
 
Table 3.  Source Parameters for the 4000 QTrap® used to analyze Oxytocin 
Source Parameter Setting 
Curtain Gas 20 
Collision Gas High 
Ion Spray Voltage 3500 volts 
Temperature 550˚C 
Ion Source Gas 1 50 
Ion Source Gas 2 50 
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Table 4. Acquisition parameters used for Oxytocin Quantification and Analysis 
Q1 
(Daltons) 
Q3 
(Daltons) 
Scan Time 
(milliseconds) 
Compound 
ID 
Declustering 
Potential (v) 
Entrance 
Potential 
(v) 
Collision 
Energy 
(v) 
Cell Exit 
Potential 
(v) 
1007.529 723.2 150 Oxytocin 1 161 10 43 18 
1007.529 86.2 150 Oxytocin 2 161 10 123 0 
1007.529 70.1 150 Oxytocin 3 161 10 129 10 				
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Table 4.  Acquisition parameters used for Oxytocin Quantification and A alysis 
Q1 
(Daltons) 
 
Q3 
(Daltons) 
 
Scan Time 
(milliseconds) 
 
Compound 
ID 
 
Declustering 
Potential 
 (v) 
Entrance 
Potential 
(v) 
Collison 
Energy 
(v) 
Cell Exit 
Potential 
(v) 
1007.529 723.2 150 Oxytocin 1 161 10 43 18 
1007.529 86.2 150 Oxytocin 2 161 10 123 0 
1007.529 70.1 150 Oxytocin 3 161 10 129 10 
 
 
2.7.2 Oxytocin Degradation Study 
Source parameters for the analysis of degradation products were the 
same as those described in Table 3.  Acquisition parameters were altered from 
selected ion monitoring mode to total ion chromatograph (TIC) mode with a scan 
range of 80 to 2800 Daltons.  The lower limit was chosen to minimize noise 
identified during initial development of this method, while the maximum limit was 
selected based upon the highest value allowed by the mass spectrometer.  
  
2.8  Oxytocin Calibration Curve 
 A calibration curve for oxytocin was created from a stock solution of 1 
µg/ml prepared by adding 4 µl of a 1 mg/ml stock solution prepared in methanol 
to 3,996 ml of methanol.  This stock solution was then used to create the 
calibrators as described in Table 5.  Calibrators were assessed from lowest to 
highest concentration, with a blank between each concentration. Two blanks 
were used after the most concentrated calibrator to assess carry over. This 
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series was repeated five times such that each single concentration preparation 
was measured in five replicate injections of the same preparation to create an 
external calibration curve. 
Table 5.  Preparation of oxytocin calibrators from a 1 µg/ml standard. 
Final Concentration 
(ng/ml) 
Standard Volume 
(µl) 
Methanol Volume  
(µl) 
1000 500 0 
900 450 50 
800 400 100 
700 350 150 
600 300 200 
500 250 250 
400 200 300 
300 150 350 
250 125 375 
200 100 400 
150 75 425 
100 50 450 
50 25 475 
20 10 490 
10 5 495 
 
2.9  Oxytocin Forced Degradation Study 
      To assess degradation levels and products of oxytocin, a solution of 10 µg/ml 
which was prepared by adding 80 µl of a 1 mg/ml oxytocin stock solution in 7,960 
ml of deionized water was utilized.  Four 1 ml aliquots of this 10 ug/ml solution 
were used.  Two samples were adjusted to a pH of 2 by the dropwise addition of 
hydrochloric acid (HCl), and two samples were adjusted to a pH of 11 by the 
dropwise addition of ammonium hydroxide.  Negative controls were created by 
adjusting 1 ml of deionized water to a pH of 2 and 11 by the dropwise addition of 
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HCl and ammonium hydroxide, respectively.   The acidic and basic degradation 
process was allowed to take place for a total of sixty minutes at ambient 
temperature and pressure.  Aliquots of 100 ml were removed from the stock vial 
at 0, 15, 30, 45 and 60 minutes.  Each aliquot was added to 400 ml of dionized 
water to reduce damage to the HPLC column from extreme pH, and then 
analyzed immediately.  This experiment was duplicated at a temperature of 90˚C.   
    
3.0 Results And Discussion 
 
3.1 Oxytocin Quantification 
 
3.1.1 Compound Optimization 
     Figure 4 is a Q1 mass spectrometer scan of an optimization solution of 
oxytocin (10 ng/ml) infused directly into the mass spectrometer, and represents 
the M+H ion of all compounds present.  As demonstrated in Figure 4, a Q1 mass 
spectrometer scan of a solution of pure oxytocin in methanol produces a series of 
1-dalton quartets at M+H, M+5, and M+22.  The quartet at 1007.9, 1008.8, 
1009.9 and 1010.9 was observed across multiple optimizations, with 1007.9 
being the maximum signal observed in the quartet.  This observation is likely 
indicative of oxytocin in various states of deamidation.  As described by Hawe18, 
a deamidation reaction, or R-CONH2R-COOH, creates a mass difference of 
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0.985 daltons. Oxytocin has three sites at which deamidation may occur; the C-
terminal Gly9, the Asn5 or the Gln4. 
       Because of the presence of this quartet, the automated compound 
optimization feature was tested in order to select the three most abundant 
product ions when the mass spectrometer was set to allow for a tolerance of +/- 2 
daltons from the precursor ion (M+H) of 1007.9.  This allowed for the inclusion of 
mono and bis-deaminated oxytocin (up to two sites deamidated).  The presence 
of these ions were then confirmed through several iterations of manual 
compound optimization27 to confirm that they were consistently present in high 
intensities.  Product ions selected were 723.2, 86.2, and 70.1 daltons.  Of these 
three ions, the 723.2 ion was observed in a previous protocol utilized by Hawe et 
al in 2009 for their research into the degradation kinetics of oxytocin, and 
represents the loss of the Pro-Leu-Gly-NH2 tripeptide from the cyclic region (OT 
minus H-C4H7NCONHC5H10CONHCH2CONH2) 17,18. The structure of the 
remaining two product fragments selected is unknown. 
       Also of note in Figure 4 are significant quartets clustered around M+H+5 
Daltons, and M+H+22 Daltons. While no structure is proposed for these 
observations, their presence may indicate a loss of precursor compound during 
storage, sample preparation, ionization, or some other source which could 
contribute to a signal loss. 
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Figure 4.  Q1 MS Scan of Oxytocin standard highlighting three 1-dalton quartets.  In blue, a 
quartet beginning with Oxytocin precursor ion (m/z) of 1007.9, in red m/z+5, and in green m/z+22. 
 
3.1.2 Oxytocin Gradient Assessment 
       The method for the quantification of oxytocin was initially kept as short as 
25 
possible to facilitate the rapid analysis of field samples for the active 
pharmaceutical ingredient.  An initial assessment of the method, as described, 
produced a single, intense peak at a retention time of 1.84 minutes with no 
visible distortion in a five minute run.  The upper and lower limit of this gradient 
was then explored by slowly altering the concentration of mobile phase B until 
peak shape became visibly distorted.  This occurred at 40:60 (A:B) and 60:40 
(A:B) respectively for the quantification method, as depicted in Figure 5. 
A 
 
B 
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C 
 
  
Figure 5.  Oxytocin Gradient Assessment  
A. Retention time and peak distortion begins to occur at 40:60 Acetonitrile:H2O  
B. Retention time and peak distortion upper limit occurs at 60:40 Acetonitrile:H2O.   
C. Retention time and peak shape of oxytocin at 50:50 acetonitrile:H2O 
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3.1.3 Oxytocin Calibration Curve 
      A calibration curve was generated with five replicates of 15 non-zero 
calibrators.  The peaks were integrated using Multi Quant® version 3.0 and the 
area of those peaks versus the known concentration is included in Figure 6.  In 
order to determine the linear dynamic range (LDR) of the method, the within run 
precision was calculated at each concentration.  This is calculated by obtaining 
the standard deviation of the area of peak detected at each concentration, 
divided by the mean peak area of that concentration to determine the within-run 
coefficient of variation (CV) of peak area.  This value is expressed as a % (%CV), 
and is shown in Table 6.  The highest % variation was present at lower 
concentrations across all three ion transitions. 
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A.) 
 
B.) 
 
Figure 6.  Signal area vs known concentration of all assessed points for oxytocin (calibrators and 
unknowns).  Product ion 1, (1007.6->723.2) is shown.  A. Linear Fit.  B. Nonlinear Fit 
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Table 6.  Peak area % CV by ion based upon five data points per ion per concentration. 
 
 
3.1.4. Linear Dynamic Range 
       A calibration curve was generated using a weighted least squares regression 
fitting and the Mulitquant™ 3.0 software package.  The linear range was defined 
as one in which five or more calibrators could be modeled linearly such that the r2 
value was at a minimum .990, according to US Pharmacopeia Validation 
Parameters31.   A summary of the r2 value obtained across different 
concentration ranges of oxytocin is provided in Table 7. For this assessment, 
calibrators and quality controls were treated equally to better assess linearity. No 
region of the data met acceptability criteria for linearity under US Pharmacopeia 
standards.  The range 150-1000 ng/ml, with a high r2 value covering the largest 
number of tested data points was instead selected as reference.  A calibration 
 Product Ion (daltons) 
Concentration (ng/ml) 723.2 86.2 70.1 
10 7.71 8.05 6.56 
20 10.03 9.32 8.53 
50 6.67 4.76 5.88 
100 3.75 4.23 2.21 
150 5.03 3.64 4.74 
200 7.66 6.60 6.81 
250 6.48 5.28 5.86 
300 4.11 5.12 4.56 
400 2.84 2.40 3.88 
500 5.17 5.99 6.47 
600 5.11 4.88 5.32 
700 4.56 5.56 4.33 
800 3.17 2.66 2.45 
900 3.81 3.49 4.32 
1000 5.38 4.15 4.21 
30 
line was generated using 6 calibration concentrations within this range.  This line 
was used to quantify unknowns and compared to a nonlinear model which was 
created with the same six concentrations.  The r2 of these two fits are located in 
the bottom of Table 7. 
 
Table 7.  Coefficient of determination ( r2) values of calibration curves generated for tested 
concentrations.  No region of tested data met acceptability criteria of >.990 when a linear 
relationship is assumed.  Values were determined using all calibrators and QC samples within 
associated range.  A linear and nonlinear fit were created using six calibrators across the 
indicated range. 
 Product Ion (daltons)  Product Ion (daltons) 
Range 
(ng/ml) 
723.2 
 
86.2 
R2 
70.1 
 
Range 
(ng/ml) 
723.2 
 
86.2 
R2 
70.1 
 
10-1000 0.968 0.968 0.967 500-1000 .982 .983 .984 
20-1000 .970 .970 .969 300-900 .983 .982 .982 
50-1000 .974 .975 .974 200-800 .982 .983 .982 
100-1000 .980 .980 .979 150-700 .979 .980 .979 
150-1000 .982 .983 .982 100-600 .982 .985 .980 
200-1000 .982 .984 .982 50-500 .980 .977 .977 
250-1000 .983 .984 .983 50-400 .973 .970 .970 
300-1000 .982 .983 .983 20-400 .973 .970 .970 
400-1000 .980 .980 .980 10-300 .965 .961 .963 
Final Linear Calibration Curve 150-1000 .985 .988 .987 
Final Nonlinear Curve 150-1000 .998 .998 .998 
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Figure 7.  Final Calibration Curve. Final range of 150-1000 ng/ml.  Shaded circles represent 
points used to generate curve.  Empty circles represent test concentrations. 
 
3.1.5  Limits of Quantification 
      The limit of quantitation is defined as the lowest non zero calibrator utilized by 
the method according to standards set forth by both the scientific working group 
on toxicology (SWGTOX) and the USP31,32.  By this definition the lower limit of 
quantification for this method is 150 ng/ml, while the upper limit is 1,000 ng/ml.   
  
3.1.6 Accuracy (Bias) 
32 
     Accuracy, or bias, was determined by calculating the difference between the 
mean of the calculated concentration and the known concentration, divided by 
the known concentration, and expressed as a percentage32 as shown in equation 
1, and summarized in Table 8.  Acceptability using SWGTOX guidelines is 
defined as +/- 20%32, while acceptability under USP is defined as +/- 2%31.  All 
values in this method were within +/- 15% when modeled linearly, leading to 
acceptance under SWGTOX criteria but requiring additional optimization to meet 
USP criteria.  This data suggests mid-concentration range is consistently 
underestimated, while high and low concentrations are overestimated. The 
accuracy is improved when a nonlinear model is employed, where the largest 
bias again seen in the mid-range (Table 8). 
Eq 1       𝑩𝒊𝒂𝒔 (%) =
[
𝑮𝒓𝒂𝒏𝒅 𝑴𝒆𝒂𝒏 𝒐𝒇 𝑪𝒂𝒍𝒄𝒖𝒍𝒂𝒕𝒆𝒅 𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏−𝑵𝒐𝒎𝒊𝒏𝒂𝒍 𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏
𝑵𝒐𝒎𝒊𝒏𝒂𝒍 𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏
] 𝒙 𝟏𝟎𝟎 
   
Table 8.  % Bias by ion per concentration of both the linear and nonlinear models.  All 
values for both models calculated with five data points/concentration 
 Linear Model Nonlinear Model 
Concentration 
Q3: 
723.2 
Q3: 
86.2 
Q3: 
70.1 
Q3: 
723.2 
Q3: 
86.2 
Q3: 
70.1 
200 3.50 2.22 2.64 
 
2.41 
 
0.87 
 
1.31 
300 -7.86 -8.87 -9.24 
 
-1.61 
 
-3.59 
 
-3.60 
500 -14.36 -14.72 -14.86 
 
-6.64 
 
-7.82 
 
-7.46 
700 -1.21 -2.17 -2.29 
 
1.90 
 
0.79 
 
0.87 
900 2.47 2.99 3.48 
 
-0.34 
 
0.26 
 
0.49 
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3.1.7  Carry Over and Minimum Distinguishable Signal 
     For the 75 blanks, the area of the largest signal peak observed at the 
appropriate retention time was 6 counts while the smallest area of the lowest 
non-zero calibrator of 10 ng was 4,752 counts. No significant carry over was 
observed in the blanks following any of the concentrations analyzed in this 
method.  The median peak area of blank samples per product ion, and their 
range are provided in Table 9. 
 
Table 9. Analysis of sample blanks based upon a sample of 75 blanks per ion. 
 Product Ion 
 723.2 86.2 70.1 
Median Peak 
Area 
18.60 
 
15.50 
 
9.30 
 
Maximum Peak 
Observed 
62.00 
 
50 
 
31.00 
 
Minimum Peak 
Observed 
0 
 
0 
 
0 
 
  
Blank values were evaluated in a histogram in Figure 9.  Visual analysis of these 
histograms suggested that the signal may not be normally distributed.  The 
Kolmogorov-Smirnov (KS) test is a non-parametric way to test the hypothesis 
that the data sets do not originate from the same distribution. In this case, the 
data set was tested against the normal and log-normal distribution33.  In both 
cases the P value was less than .01 suggesting these data are not well 
characterized by the normal or log-normal distribution classes.  Since the data is 
not well classified as normal or log normal, the traditional methods to determine 
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the minimum distinguishable signal described by Curie and Mocack34,35 are not 
applied, instead the minimum distinguishable signal is defined as the maximum 
noise peak height for each ion, which is 62, 50 and 31.00 counts for product ions 
732.2, 86.2 and 70.1 respectively. 
A
 
B
 
  
C  
Figure 9.  Histogram of Blank Signal Area based upon 75 observations per ion. For Ions A.) 
723.2, B.) 86.2 and C.) 70.1 Daltons. 
 
To further explore the minimum distinguishable signal, the region of the 
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origin, was fitted using a weighted least squares regression linear model the 
MultiQuant™ software as described in section 3.1.3, and an online tool36.    The 
regression lines, their r2 values, and the y-intercept are included in Table 10.  For 
all product ions the y-intercept is negative.  Additionally, the y-intercept plus three 
times its standard error was  -107.06, 210.3, and -58.12 for ions 723.2, 86.2 
and 70.1 respectively, indicating that this calibration-based method is unsuitable 
for determining minimum distinguishable signal.  These results again suggest 
that there may be a confounding factor associated with these signal 
measurements and it emphasizes the need for additional protocol development. 
 Since the noise exhibited in this method is neither normally nor log 
normally distributed, and has a y intercept value that is negative the minimum 
distinguishable signal will be defined as any value greater than the maximum 
blank signal observed, as noted in Table 9. 
 
Table 10.  Minimum Distinguishable Signal 
Ion 723.2 86.2 70.1 
Slope 689.2x 233.61x 228.44x 
r = 0.993 0.994 0.994 
y intercept -1700 -567 -601 
Standard 
Error 530.98 259.1 180.96 
 
 
3.1.8.  Calibration and Analytical Sensitivity 
      Calibration sensitivity is defined as the expected change in signal per unit 
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change in concentration, or slope of the calibration curve.  Analytical sensitivity 
provides a measure of the change in concentration that can be discerned by the 
method35.  This is determined by dividing the calibration sensitivity by the 
standard deviation at that concentration.  The calibration sensitivity over the 
range of the calibration curve is depicted in Table 12.  The 723.2 product ion had 
the highest calibration sensitivity, nearly three times that of the other ions 
assessed.  Its high standard deviation, however, resulted in comparable 
analytical sensitivity. 
 
Table 12.  Analytical and Calibration Sensitivity by product ion. 
 Analytical Sensitivity 
 723.2 86.2 70.1 
150 0.27 0.38 0.29 
200 0.12 0.14 0.13 
250 0.11 0.13 0.12 
300 0.13 0.11 0.12 
400 0.13 0.15 0.09 
500 0.06 0.05 0.05 
600 0.04 0.04 0.04 
700 0.04 0.03 0.04 
800 0.05 0.05 0.06 
900 0.03 0.03 0.03 
1000 0.02 0.02 0.02 
Calibration 
Sensitivity 1435 494 486 
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3.2 Oxytocin Degradation Analysis 
Oxytocin prepared in an acidic and basic environments were allowed to sit 
at room temperature and at 90 degrees Celsius for a period of one hour.  
Samples were compared to control samples containing no oxytocin, and 
evaluated for the presence of degradation products.  The samples were analyzed 
in Q1 MS or TIC mode.  Oxytocin was identified in all noncontrol samples.  The 
sample that was allowed to sit at 90˚C for 60 minutes was not evaluated due lack 
of remaining sample volume. 
 As the samples of prepared oxytocin had concentration well above the 
regions of linearity identified in section 3.1.4, and also well above the 
concentration at which the detector exhibits a linear response, the value does not 
correlate directly to a concentration.  There was no significant reduction in peak 
height over time noted in any observed conditions, although due to detector 
saturation no conclusions may be drawn from this observation.  Further, no 
additional degradation products were identified in basic conditions.  One 
additional peak was observed when oxytocin was allowed to sit in acidic 
conditions, as seen in Figure 10, but this peak was identified in the acidic control 
sample as well and may be representative column-bleed due to the caustic 
conditions.  All samples exhibited a high degree of baseline noise associated 
with the Q1 MS scan mode.  Because of this, the samples were additionally 
analyzed by filtering the spectra for the m/z of known degradation products15,16,18, 
which also identified no peaks of interest. 
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Figure 10.  Oxytocin degradation after 1 hour at room temperature in acidic 
conditions (top) vs its blank (bottom).  The only observed peaks are Oxytocin 
(labeled, and indicated), and two poorly shaped peaks that are believed to be 
column bleed due to the caustic solution. 
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4. CONCLUSIONS 
 
Table 13. Summary of evaluated metrics across all product ions. 
 723.2 86.2 70.1 
Signal %CV (Min) 2.85 2.40 2.21 
Signal %CV (Max) 10.04 9.32 8.53 
Average STD (150 ng/ml) 5323 1299 1691 
Calibration Sensitivity (linear) 1435 494 486 
Average Analytical Sensitivity (linear) 0.07 0.07 0.07 
Median Signal (150ng/ml) 5230 1760 1696 
Noise (MDS) 62.00 49.61 31.00 
Median Signal (150ng/mL) : Median  Noise 84.36 35.49 54.71 
%Bias (150-1000 ng) Max (Linear) 14.37 14.72 14.86 
%Bias (150-1000 ng) Max (Non-Linear) 6.64 7.82 7.47 
  
A summary of all metrics evaluated for comparative analysis between the 
three product ions selected is provided in Table 14.  Of the three product ions 
assessed for oxytocin, the 1007.3 723.2 ion was observed to have the highest 
signal across all concentrations.  While it does demonstrate a calibration 
sensitivity three times that of the other ions assessed, it had a correspondingly 
high standard deviation, resulting in an analytical sensitivity that was not 
sufficiently different across the observed product ions.  The 723.2 ion’s large 
mass is unusual amongst pharmaceuticals, and placed it well above the noise 
threshold in the degradation analysis.  It was therefore selected as the 
quantitation ion for this method.  While the remaining two ions were 
comparatively similar across all assessed metrics, the 1007.370.1 was 
selected as the qualifier ion. 
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 This method demonstrates a low minimum distinguishable signal, and was 
successful in detecting oxytocin in concentrations as low as 10ng/ml. This is 
similar to the range achieved by Karbiwnyk et al in 2008, which had a LOD of 2.1 
ng/ml and a linear range of 7.3-115 ng/ml using LC- ion trap mass 
spectrometry17.  While the UFLC-MS/MS method may be used to screen for the 
presence or absence of oxytocin to identify counterfeit material containing no 
active ingredient, this method does not demonstrate sufficient accuracy by USP 
guidelines to be considered a validated method for the quantification of 
oxytocin31. Further protocol development, and identification of factors reducing 
linearity may be required in order to categorize this method as fit-for-purpose.  It 
is presently more effective to model this protocol using a nonlinear model, but 
even the nonlinear model is not within validation parameters identified by the 
USP.   
 
5.0 Future Research 
5.1 Oxytocin 
 While reducing the method from three to two ions will increase sensitivity, 
additional optimization is required to bring this method into compliance with USP 
guidelines of +/-2% accuracy31.  Further, the structure of the 70.1 ion is unknown 
at this time.  Elucidating the structure of this fragment may provide insight into 
the specificity of these fragments to biologically active oxytocin. 
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 Identifying the structure of the quartets observed during compound 
optimization in the Q1 mass spectra may also provide insight into the reduction of 
linear response observed in this experiment.  The observation in a pure standard 
of what is proposed to be oxytocin in various states of deamidation, and the 
occurrence of the two unknown quartets at m/z+5 and m/z+22 could be relevant 
to the variation in biological effectiveness between equivalent doses of oxytocin. 
Degradation analysis of oxytocin revealed no peaks of interest that could 
be used for specificity testing.  While it is known that oxytocin can form 
trimers15,18, which are above the upper detection limit of the mass spectrometer, 
other poly sulfonated products described in literature15, as well as dimers, are 
within mass detection limits.  This suggests that these products did not form, or 
were unable to be resolved from the precursor peak of oxytocin with this method. 
 
 
5.2 Artesunate/Amodiaquine 
 At this time no mobile phase tested was compatible with UFLC 
manufacturer guidelines.  Each mobile phase tested has not produced sufficient 
signal to continue development of a UFLC/MS/MS protocol for the quantification 
of artesunate or amodiaquine.  Additional testing of compatible mobile phases is 
required before method development may continue.  
  
42 
APPENDIX A:  Mobile phases tested for artesunate/amodiaquine which yielded 
no significant signal during protocol development. 
 
Mobile Phase A Mobile Phase B Observed Signal 
2mm Formic Acid  Methanol None 
10 mm Formic Acid Methanol None 
Deionized Water Acetonitrile None 
Deionized Water Methanol None 
2mm Ammonium Formate Acetonitrile None 
10 mm Ammonium Formate Acetonitrile None 
 
All mobile phases noted were tested within a 10 minute analytical period at 
gradients ranging from 10-90% B for any observed signal across 6-12 proposed 
transition ions of artesunate/amodiaquine.  Samples were assessed at a 
concentration of 1000 ng/ml.  A representative spectra indicative of a negative 
result is included below as Figure 11.  Note poor signal quality (200 cps), a lack 
of shape, and a lack or correlation amongst ions. At this time no mobile phase 
compatible with a C18 column has been identified. 
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Figure 11.  A Representative Negative Result for Artesunate/Amodiaquine Mobile Phase 
selection. 
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